#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Selective functional connectivity abnormality of the transition zone of the inferior parietal lobule in schizophrenia Structural and functional alterations in the inferior parietal lobule (IPL) in schizophrenia have been frequently reported; however, the IPL connectivity changes in schizophrenia remain largely unknown.
1-1	0-9	Selective	_
1-2	10-20	functional	_
1-3	21-33	connectivity	_
1-4	34-45	abnormality	_
1-5	46-48	of	_
1-6	49-52	the	_
1-7	53-63	transition	_
1-8	64-68	zone	_
1-9	69-71	of	_
1-10	72-75	the	_
1-11	76-84	inferior	_
1-12	85-93	parietal	_
1-13	94-100	lobule	_
1-14	101-103	in	_
1-15	104-117	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-16	118-128	Structural	_
1-17	129-132	and	_
1-18	133-143	functional	_
1-19	144-155	alterations	_
1-20	156-158	in	_
1-21	159-162	the	_
1-22	163-171	inferior	_
1-23	172-180	parietal	_
1-24	181-187	lobule	_
1-25	188-189	(	_
1-26	190-193	IPL	_
1-27	194-195	)	_
1-28	196-198	in	_
1-29	199-212	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-30	213-217	have	_
1-31	218-222	been	_
1-32	223-233	frequently	_
1-33	234-242	reported	_
1-34	243-244	;	_
1-35	245-252	however	_
1-36	253-254	,	_
1-37	255-258	the	_
1-38	259-262	IPL	_
1-39	263-275	connectivity	_
1-40	276-283	changes	_
1-41	284-286	in	_
1-42	287-300	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-43	301-307	remain	_
1-44	308-315	largely	_
1-45	316-323	unknown	_
1-46	324-325	.	_

Text=Based on heterogeneity of the IPL in structure, connection and function, we hypothesize that the resting-state functional connectivities (rsFCs) of the IPL subregions are differentially affected in schizophrenia.
2-1	326-331	Based	_
2-2	332-334	on	_
2-3	335-348	heterogeneity	_
2-4	349-351	of	_
2-5	352-355	the	_
2-6	356-359	IPL	_
2-7	360-362	in	_
2-8	363-372	structure	_
2-9	373-374	,	_
2-10	375-385	connection	_
2-11	386-389	and	_
2-12	390-398	function	_
2-13	399-400	,	_
2-14	401-403	we	_
2-15	404-415	hypothesize	_
2-16	416-420	that	_
2-17	421-424	the	_
2-18	425-438	resting-state	_
2-19	439-449	functional	_
2-20	450-464	connectivities	_
2-21	465-466	(	_
2-22	467-472	rsFCs	_
2-23	473-474	)	_
2-24	475-477	of	_
2-25	478-481	the	_
2-26	482-485	IPL	_
2-27	486-496	subregions	_
2-28	497-500	are	_
2-29	501-515	differentially	_
2-30	516-524	affected	_
2-31	525-527	in	_
2-32	528-541	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-33	542-543	.	_

Text=This study included 95 schizophrenia patients and 104 healthy controls.
3-1	544-548	This	_
3-2	549-554	study	_
3-3	555-563	included	_
3-4	564-566	95	_
3-5	567-580	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-6	581-589	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-7	590-593	and	_
3-8	594-597	104	_
3-9	598-605	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-10	606-614	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-11	615-616	.	_

Text=The IPL subregions were defined according to a previous in vivo connection-based parcellation study.
4-1	617-620	The	_
4-2	621-624	IPL	_
4-3	625-635	subregions	_
4-4	636-640	were	_
4-5	641-648	defined	_
4-6	649-658	according	_
4-7	659-661	to	_
4-8	662-663	a	_
4-9	664-672	previous	_
4-10	673-675	in	_
4-11	676-680	vivo	_
4-12	681-697	connection-based	_
4-13	698-710	parcellation	_
4-14	711-716	study	_
4-15	717-718	.	_

Text=We calculated the rsFC of each IPL subregion and compared them between the two groups while controlling for the effects of age, gender, and grey matter volume.
5-1	719-721	We	_
5-2	722-732	calculated	_
5-3	733-736	the	_
5-4	737-741	rsFC	_
5-5	742-744	of	_
5-6	745-749	each	_
5-7	750-753	IPL	_
5-8	754-763	subregion	_
5-9	764-767	and	_
5-10	768-776	compared	_
5-11	777-781	them	_
5-12	782-789	between	_
5-13	790-793	the	_
5-14	794-797	two	_
5-15	798-804	groups	_
5-16	805-810	while	_
5-17	811-822	controlling	_
5-18	823-826	for	_
5-19	827-830	the	_
5-20	831-838	effects	_
5-21	839-841	of	_
5-22	842-845	age	_
5-23	846-847	,	_
5-24	848-854	gender	_
5-25	855-856	,	_
5-26	857-860	and	_
5-27	861-865	grey	_
5-28	866-872	matter	_
5-29	873-879	volume	_
5-30	880-881	.	_

Text=Among the six subregions of the left IPL and the five subregions of the right IPL, only the bilateral PFm (a transition zone of the IPL) subregions exhibited abnormal rsFC in schizophrenia.
6-1	882-887	Among	_
6-2	888-891	the	_
6-3	892-895	six	_
6-4	896-906	subregions	_
6-5	907-909	of	_
6-6	910-913	the	_
6-7	914-918	left	_
6-8	919-922	IPL	_
6-9	923-926	and	_
6-10	927-930	the	_
6-11	931-935	five	_
6-12	936-946	subregions	_
6-13	947-949	of	_
6-14	950-953	the	_
6-15	954-959	right	_
6-16	960-963	IPL	_
6-17	964-965	,	_
6-18	966-970	only	_
6-19	971-974	the	_
6-20	975-984	bilateral	_
6-21	985-988	PFm	_
6-22	989-990	(	_
6-23	991-992	a	_
6-24	993-1003	transition	_
6-25	1004-1008	zone	_
6-26	1009-1011	of	_
6-27	1012-1015	the	_
6-28	1016-1019	IPL	_
6-29	1020-1021	)	_
6-30	1022-1032	subregions	_
6-31	1033-1042	exhibited	_
6-32	1043-1051	abnormal	_
6-33	1052-1056	rsFC	_
6-34	1057-1059	in	_
6-35	1060-1073	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-36	1074-1075	.	_

Text=Specifically, the left PFm showed increased rsFC with the bilateral lingual gyri in schizophrenia patients than in healthy controls.
7-1	1076-1088	Specifically	_
7-2	1089-1090	,	_
7-3	1091-1094	the	_
7-4	1095-1099	left	_
7-5	1100-1103	PFm	_
7-6	1104-1110	showed	_
7-7	1111-1120	increased	_
7-8	1121-1125	rsFC	_
7-9	1126-1130	with	_
7-10	1131-1134	the	_
7-11	1135-1144	bilateral	_
7-12	1145-1152	lingual	_
7-13	1153-1157	gyri	_
7-14	1158-1160	in	_
7-15	1161-1174	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-16	1175-1183	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-17	1184-1188	than	_
7-18	1189-1191	in	_
7-19	1192-1199	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-20	1200-1208	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-21	1209-1210	.	_

Text=The right PFm exhibited increased rsFC with the right lingual gyrus and inferior occipital gyrus, and bilateral mid-cingulate and sensorimotor cortices in schizophrenia patients.
8-1	1211-1214	The	_
8-2	1215-1220	right	_
8-3	1221-1224	PFm	_
8-4	1225-1234	exhibited	_
8-5	1235-1244	increased	_
8-6	1245-1249	rsFC	_
8-7	1250-1254	with	_
8-8	1255-1258	the	_
8-9	1259-1264	right	_
8-10	1265-1272	lingual	_
8-11	1273-1278	gyrus	_
8-12	1279-1282	and	_
8-13	1283-1291	inferior	_
8-14	1292-1301	occipital	_
8-15	1302-1307	gyrus	_
8-16	1308-1309	,	_
8-17	1310-1313	and	_
8-18	1314-1323	bilateral	_
8-19	1324-1337	mid-cingulate	_
8-20	1338-1341	and	_
8-21	1342-1354	sensorimotor	_
8-22	1355-1363	cortices	_
8-23	1364-1366	in	_
8-24	1367-1380	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-25	1381-1389	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-26	1390-1391	.	_

Text=These findings suggest a selective rsFC abnormality in the IPL subregions in schizophrenia, characterized by the increased rsFC between the PFm subregion of the IPL and the visual and sensorimotor areas.
9-1	1392-1397	These	_
9-2	1398-1406	findings	_
9-3	1407-1414	suggest	_
9-4	1415-1416	a	_
9-5	1417-1426	selective	_
9-6	1427-1431	rsFC	_
9-7	1432-1443	abnormality	_
9-8	1444-1446	in	_
9-9	1447-1450	the	_
9-10	1451-1454	IPL	_
9-11	1455-1465	subregions	_
9-12	1466-1468	in	_
9-13	1469-1482	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-14	1483-1484	,	_
9-15	1485-1498	characterized	_
9-16	1499-1501	by	_
9-17	1502-1505	the	_
9-18	1506-1515	increased	_
9-19	1516-1520	rsFC	_
9-20	1521-1528	between	_
9-21	1529-1532	the	_
9-22	1533-1536	PFm	_
9-23	1537-1546	subregion	_
9-24	1547-1549	of	_
9-25	1550-1553	the	_
9-26	1554-1557	IPL	_
9-27	1558-1561	and	_
9-28	1562-1565	the	_
9-29	1566-1572	visual	_
9-30	1573-1576	and	_
9-31	1577-1589	sensorimotor	_
9-32	1590-1595	areas	_
9-33	1596-1597	.	_

Text=Highlights Investigation of the subregional-level rsFC changes of the IPL in schizophrenia The PFm is only IPL subregion with significant rsFC changes in schizophrenia.
10-1	1598-1608	Highlights	_
10-2	1609-1622	Investigation	_
10-3	1623-1625	of	_
10-4	1626-1629	the	_
10-5	1630-1647	subregional-level	_
10-6	1648-1652	rsFC	_
10-7	1653-1660	changes	_
10-8	1661-1663	of	_
10-9	1664-1667	the	_
10-10	1668-1671	IPL	_
10-11	1672-1674	in	_
10-12	1675-1688	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-13	1689-1692	The	_
10-14	1693-1696	PFm	_
10-15	1697-1699	is	_
10-16	1700-1704	only	_
10-17	1705-1708	IPL	_
10-18	1709-1718	subregion	_
10-19	1719-1723	with	_
10-20	1724-1735	significant	_
10-21	1736-1740	rsFC	_
10-22	1741-1748	changes	_
10-23	1749-1751	in	_
10-24	1752-1765	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-25	1766-1767	.	_

Text=Suggesting a selective rsFC abnormality in the IPL subregions in schizophrenia Materials and methods Participants A total of 102 schizophrenia patients and 104 healthy subjects were recruited for this study.
11-1	1768-1778	Suggesting	_
11-2	1779-1780	a	_
11-3	1781-1790	selective	_
11-4	1791-1795	rsFC	_
11-5	1796-1807	abnormality	_
11-6	1808-1810	in	_
11-7	1811-1814	the	_
11-8	1815-1818	IPL	_
11-9	1819-1829	subregions	_
11-10	1830-1832	in	_
11-11	1833-1846	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-12	1847-1856	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-13	1857-1860	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-14	1861-1868	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-15	1869-1881	Participants	_
11-16	1882-1883	A	_
11-17	1884-1889	total	_
11-18	1890-1892	of	_
11-19	1893-1896	102	_
11-20	1897-1910	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-21	1911-1919	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-22	1920-1923	and	_
11-23	1924-1927	104	_
11-24	1928-1935	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-25	1936-1944	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-26	1945-1949	were	_
11-27	1950-1959	recruited	_
11-28	1960-1963	for	_
11-29	1964-1968	this	_
11-30	1969-1974	study	_
11-31	1975-1976	.	_

Text=Diagnoses for patients were confirmed using the Structured Clinical Interview for DSM-IV.
12-1	1977-1986	Diagnoses	_
12-2	1987-1990	for	_
12-3	1991-1999	patients	_
12-4	2000-2004	were	_
12-5	2005-2014	confirmed	_
12-6	2015-2020	using	_
12-7	2021-2024	the	_
12-8	2025-2035	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-9	2036-2044	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-10	2045-2054	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-11	2055-2058	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-12	2059-2065	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-13	2066-2067	.	_

Text=Inclusion criteria were age (16–60 years) and right-handedness.
13-1	2068-2077	Inclusion	_
13-2	2078-2086	criteria	_
13-3	2087-2091	were	_
13-4	2092-2095	age	_
13-5	2096-2097	(	_
13-6	2098-2103	16–60	_
13-7	2104-2109	years	_
13-8	2110-2111	)	_
13-9	2112-2115	and	_
13-10	2116-2132	right-handedness	_
13-11	2133-2134	.	_

Text=Exclusion criteria included MRI contraindications, poor image quality, presence of a systemic medical illness (i.e., cardiovascular disease, diabetes) or CNS disorder (i.e., stroke, epilepsy), history of head trauma, and substance abuse within the last 3 months or lifetime history of substance abuse or dependence.
14-1	2135-2144	Exclusion	_
14-2	2145-2153	criteria	_
14-3	2154-2162	included	_
14-4	2163-2166	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
14-5	2167-2184	contraindications	_
14-6	2185-2186	,	_
14-7	2187-2191	poor	_
14-8	2192-2197	image	_
14-9	2198-2205	quality	_
14-10	2206-2207	,	_
14-11	2208-2216	presence	_
14-12	2217-2219	of	_
14-13	2220-2221	a	_
14-14	2222-2230	systemic	_
14-15	2231-2238	medical	_
14-16	2239-2246	illness	_
14-17	2247-2248	(	_
14-18	2249-2253	i.e.	_
14-19	2254-2255	,	_
14-20	2256-2270	cardiovascular	_
14-21	2271-2278	disease	_
14-22	2279-2280	,	_
14-23	2281-2289	diabetes	_
14-24	2290-2291	)	_
14-25	2292-2294	or	_
14-26	2295-2298	CNS	_
14-27	2299-2307	disorder	_
14-28	2308-2309	(	_
14-29	2310-2314	i.e.	_
14-30	2315-2316	,	_
14-31	2317-2323	stroke	_
14-32	2324-2325	,	_
14-33	2326-2334	epilepsy	_
14-34	2335-2336	)	_
14-35	2337-2338	,	_
14-36	2339-2346	history	_
14-37	2347-2349	of	_
14-38	2350-2354	head	_
14-39	2355-2361	trauma	_
14-40	2362-2363	,	_
14-41	2364-2367	and	_
14-42	2368-2377	substance	_
14-43	2378-2383	abuse	_
14-44	2384-2390	within	_
14-45	2391-2394	the	_
14-46	2395-2399	last	_
14-47	2400-2401	3	_
14-48	2402-2408	months	_
14-49	2409-2411	or	_
14-50	2412-2420	lifetime	_
14-51	2421-2428	history	_
14-52	2429-2431	of	_
14-53	2432-2441	substance	_
14-54	2442-2447	abuse	_
14-55	2448-2450	or	_
14-56	2451-2461	dependence	_
14-57	2462-2463	.	_

Text=Additional exclusion criteria for healthy subjects were history of any Axis I or II disorders and a psychotic disorder and first-degree relative with a psychotic disorder.
15-1	2464-2474	Additional	_
15-2	2475-2484	exclusion	_
15-3	2485-2493	criteria	_
15-4	2494-2497	for	_
15-5	2498-2505	healthy	_
15-6	2506-2514	subjects	_
15-7	2515-2519	were	_
15-8	2520-2527	history	_
15-9	2528-2530	of	_
15-10	2531-2534	any	_
15-11	2535-2539	Axis	_
15-12	2540-2541	I	_
15-13	2542-2544	or	_
15-14	2545-2547	II	_
15-15	2548-2557	disorders	_
15-16	2558-2561	and	_
15-17	2562-2563	a	_
15-18	2564-2573	psychotic	_
15-19	2574-2582	disorder	_
15-20	2583-2586	and	_
15-21	2587-2599	first-degree	_
15-22	2600-2608	relative	_
15-23	2609-2613	with	_
15-24	2614-2615	a	_
15-25	2616-2625	psychotic	_
15-26	2626-2634	disorder	_
15-27	2635-2636	.	_

Text=After excluding seven patients with excessive head motion (translational or rotational motion parameters more than 2 mm or 2°), 95 schizophrenia patients and 104 healthy subjects were finally included in further analysis.
16-1	2637-2642	After	_
16-2	2643-2652	excluding	_
16-3	2653-2658	seven	_
16-4	2659-2667	patients	_
16-5	2668-2672	with	_
16-6	2673-2682	excessive	_
16-7	2683-2687	head	_
16-8	2688-2694	motion	_
16-9	2695-2696	(	_
16-10	2697-2710	translational	_
16-11	2711-2713	or	_
16-12	2714-2724	rotational	_
16-13	2725-2731	motion	_
16-14	2732-2742	parameters	_
16-15	2743-2747	more	_
16-16	2748-2752	than	_
16-17	2753-2754	2	_
16-18	2755-2757	mm	_
16-19	2758-2760	or	_
16-20	2761-2763	2°	_
16-21	2764-2765	)	_
16-22	2766-2767	,	_
16-23	2768-2770	95	_
16-24	2771-2784	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-25	2785-2793	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-26	2794-2797	and	_
16-27	2798-2801	104	_
16-28	2802-2809	healthy	_
16-29	2810-2818	subjects	_
16-30	2819-2823	were	_
16-31	2824-2831	finally	_
16-32	2832-2840	included	_
16-33	2841-2843	in	_
16-34	2844-2851	further	_
16-35	2852-2860	analysis	_
16-36	2861-2862	.	_

Text=Clinical symptoms were quantified with the Positive and Negative Syndrome Scale (PANSS).
17-1	2863-2871	Clinical	_
17-2	2872-2880	symptoms	_
17-3	2881-2885	were	_
17-4	2886-2896	quantified	_
17-5	2897-2901	with	_
17-6	2902-2905	the	_
17-7	2906-2914	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-8	2915-2918	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-9	2919-2927	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-10	2928-2936	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-11	2937-2942	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-12	2943-2944	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-13	2945-2950	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-14	2951-2952	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
17-15	2953-2954	.	_

Text=This study was approved by the Medical Research Ethics Committee at Tianjin Medical University General Hospital.
18-1	2955-2959	This	_
18-2	2960-2965	study	_
18-3	2966-2969	was	_
18-4	2970-2978	approved	_
18-5	2979-2981	by	_
18-6	2982-2985	the	_
18-7	2986-2993	Medical	_
18-8	2994-3002	Research	_
18-9	3003-3009	Ethics	_
18-10	3010-3019	Committee	_
18-11	3020-3022	at	_
18-12	3023-3030	Tianjin	_
18-13	3031-3038	Medical	_
18-14	3039-3049	University	_
18-15	3050-3057	General	_
18-16	3058-3066	Hospital	_
18-17	3067-3068	.	_

Text=All participants were clearly informed about the whole study, and written informed consent was obtained from each participant.
19-1	3069-3072	All	_
19-2	3073-3085	participants	_
19-3	3086-3090	were	_
19-4	3091-3098	clearly	_
19-5	3099-3107	informed	_
19-6	3108-3113	about	_
19-7	3114-3117	the	_
19-8	3118-3123	whole	_
19-9	3124-3129	study	_
19-10	3130-3131	,	_
19-11	3132-3135	and	_
19-12	3136-3143	written	_
19-13	3144-3152	informed	_
19-14	3153-3160	consent	_
19-15	3161-3164	was	_
19-16	3165-3173	obtained	_
19-17	3174-3178	from	_
19-18	3179-3183	each	_
19-19	3184-3195	participant	_
19-20	3196-3197	.	_

Text=Imaging data acquisition MRI was performed using a 3.0-Tesla MR system (Discovery MR750, General Electric, Milwaukee, WI, USA).
20-1	3198-3205	Imaging	_
20-2	3206-3210	data	_
20-3	3211-3222	acquisition	_
20-4	3223-3226	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
20-5	3227-3230	was	_
20-6	3231-3240	performed	_
20-7	3241-3246	using	_
20-8	3247-3248	a	_
20-9	3249-3258	3.0-Tesla	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
20-10	3259-3261	MR	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
20-11	3262-3268	system	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
20-12	3269-3270	(	_
20-13	3271-3280	Discovery	_
20-14	3281-3286	MR750	_
20-15	3287-3288	,	_
20-16	3289-3296	General	_
20-17	3297-3305	Electric	_
20-18	3306-3307	,	_
20-19	3308-3317	Milwaukee	_
20-20	3318-3319	,	_
20-21	3320-3322	WI	_
20-22	3323-3324	,	_
20-23	3325-3328	USA	_
20-24	3329-3330	)	_
20-25	3331-3332	.	_

Text=Tight but comfortable foam padding was used to minimize head motion, and earplugs were used to reduce scanner noise.
21-1	3333-3338	Tight	_
21-2	3339-3342	but	_
21-3	3343-3354	comfortable	_
21-4	3355-3359	foam	_
21-5	3360-3367	padding	_
21-6	3368-3371	was	_
21-7	3372-3376	used	_
21-8	3377-3379	to	_
21-9	3380-3388	minimize	_
21-10	3389-3393	head	_
21-11	3394-3400	motion	_
21-12	3401-3402	,	_
21-13	3403-3406	and	_
21-14	3407-3415	earplugs	_
21-15	3416-3420	were	_
21-16	3421-3425	used	_
21-17	3426-3428	to	_
21-18	3429-3435	reduce	_
21-19	3436-3443	scanner	_
21-20	3444-3449	noise	_
21-21	3450-3451	.	_

Text=Sagittal 3D T1-weighted images were acquired by a brain volume sequence with the following parameters: repetition time (TR) = 8.2 ms; echo time (TE) = 3.2 ms; inversion time = 450 ms; flip angle (FA) = 12°; field of view (FOV) = 256 mm × 256 mm; matrix = 256 × 256; slice thickness = 1 mm, no gap; and 188 sagittal slices.
22-1	3452-3460	Sagittal	http://maven.renci.org/NeuroBridge/neurobridge#DigitalScale
22-2	3461-3463	3D	http://maven.renci.org/NeuroBridge/neurobridge#DigitalScale
22-3	3464-3475	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
22-4	3476-3482	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
22-5	3483-3487	were	_
22-6	3488-3496	acquired	_
22-7	3497-3499	by	_
22-8	3500-3501	a	_
22-9	3502-3507	brain	_
22-10	3508-3514	volume	_
22-11	3515-3523	sequence	_
22-12	3524-3528	with	_
22-13	3529-3532	the	_
22-14	3533-3542	following	_
22-15	3543-3553	parameters	_
22-16	3554-3555	:	_
22-17	3556-3566	repetition	_
22-18	3567-3571	time	_
22-19	3572-3573	(	_
22-20	3574-3576	TR	_
22-21	3577-3578	)	_
22-22	3579-3580	=	_
22-23	3581-3584	8.2	_
22-24	3585-3587	ms	_
22-25	3588-3589	;	_
22-26	3590-3594	echo	_
22-27	3595-3599	time	_
22-28	3600-3601	(	_
22-29	3602-3604	TE	_
22-30	3605-3606	)	_
22-31	3607-3608	=	_
22-32	3609-3612	3.2	_
22-33	3613-3615	ms	_
22-34	3616-3617	;	_
22-35	3618-3627	inversion	_
22-36	3628-3632	time	_
22-37	3633-3634	=	_
22-38	3635-3638	450	_
22-39	3639-3641	ms	_
22-40	3642-3643	;	_
22-41	3644-3648	flip	_
22-42	3649-3654	angle	_
22-43	3655-3656	(	_
22-44	3657-3659	FA	_
22-45	3660-3661	)	_
22-46	3662-3663	=	_
22-47	3664-3667	12°	_
22-48	3668-3669	;	_
22-49	3670-3675	field	_
22-50	3676-3678	of	_
22-51	3679-3683	view	_
22-52	3684-3685	(	_
22-53	3686-3689	FOV	_
22-54	3690-3691	)	_
22-55	3692-3693	=	_
22-56	3694-3697	256	_
22-57	3698-3700	mm	_
22-58	3701-3702	×	_
22-59	3703-3706	256	_
22-60	3707-3709	mm	_
22-61	3710-3711	;	_
22-62	3712-3718	matrix	_
22-63	3719-3720	=	_
22-64	3721-3724	256	_
22-65	3725-3726	×	_
22-66	3727-3730	256	_
22-67	3731-3732	;	_
22-68	3733-3738	slice	_
22-69	3739-3748	thickness	_
22-70	3749-3750	=	_
22-71	3751-3752	1	_
22-72	3753-3755	mm	_
22-73	3756-3757	,	_
22-74	3758-3760	no	_
22-75	3761-3764	gap	_
22-76	3765-3766	;	_
22-77	3767-3770	and	_
22-78	3771-3774	188	_
22-79	3775-3783	sagittal	_
22-80	3784-3790	slices	_
22-81	3791-3792	.	_

Text=The resting-state functional MRI (rs-fMRI) data were acquired using a gradient-echo single-short echo planar imaging sequence with the following parameters: TR/TE = 2000/45 ms; FOV = 220 mm × 220 mm; matrix = 64 × 64; FA = 90°; slice thickness = 4 mm; gap = 0.5 mm; 32 interleaved transverse slices; and 180 volumes.
23-1	3793-3796	The	_
23-2	3797-3810	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
23-3	3811-3821	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
23-4	3822-3825	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
23-5	3826-3827	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
23-6	3828-3835	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
23-7	3836-3837	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
23-8	3838-3842	data	_
23-9	3843-3847	were	_
23-10	3848-3856	acquired	_
23-11	3857-3862	using	_
23-12	3863-3864	a	_
23-13	3865-3878	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
23-14	3879-3891	single-short	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
23-15	3892-3896	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
23-16	3897-3903	planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
23-17	3904-3911	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
23-18	3912-3920	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
23-19	3921-3925	with	_
23-20	3926-3929	the	_
23-21	3930-3939	following	_
23-22	3940-3950	parameters	_
23-23	3951-3952	:	_
23-24	3953-3958	TR/TE	_
23-25	3959-3960	=	_
23-26	3961-3968	2000/45	_
23-27	3969-3971	ms	_
23-28	3972-3973	;	_
23-29	3974-3977	FOV	_
23-30	3978-3979	=	_
23-31	3980-3983	220	_
23-32	3984-3986	mm	_
23-33	3987-3988	×	_
23-34	3989-3992	220	_
23-35	3993-3995	mm	_
23-36	3996-3997	;	_
23-37	3998-4004	matrix	_
23-38	4005-4006	=	_
23-39	4007-4009	64	_
23-40	4010-4011	×	_
23-41	4012-4014	64	_
23-42	4015-4016	;	_
23-43	4017-4019	FA	_
23-44	4020-4021	=	_
23-45	4022-4025	90°	_
23-46	4026-4027	;	_
23-47	4028-4033	slice	_
23-48	4034-4043	thickness	_
23-49	4044-4045	=	_
23-50	4046-4047	4	_
23-51	4048-4050	mm	_
23-52	4051-4052	;	_
23-53	4053-4056	gap	_
23-54	4057-4058	=	_
23-55	4059-4062	0.5	_
23-56	4063-4065	mm	_
23-57	4066-4067	;	_
23-58	4068-4070	32	_
23-59	4071-4082	interleaved	_
23-60	4083-4093	transverse	_
23-61	4094-4100	slices	_
23-62	4101-4102	;	_
23-63	4103-4106	and	_
23-64	4107-4110	180	_
23-65	4111-4118	volumes	_
23-66	4119-4120	.	_

Text=During rs-fMRI scans, all subjects were instructed to keep their eyes closed, to relax and move as little as possible, to think of nothing in particular, and not to fall asleep.
24-1	4121-4127	During	_
24-2	4128-4135	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
24-3	4136-4141	scans	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
24-4	4142-4143	,	_
24-5	4144-4147	all	_
24-6	4148-4156	subjects	_
24-7	4157-4161	were	_
24-8	4162-4172	instructed	_
24-9	4173-4175	to	_
24-10	4176-4180	keep	_
24-11	4181-4186	their	_
24-12	4187-4191	eyes	_
24-13	4192-4198	closed	_
24-14	4199-4200	,	_
24-15	4201-4203	to	_
24-16	4204-4209	relax	_
24-17	4210-4213	and	_
24-18	4214-4218	move	_
24-19	4219-4221	as	_
24-20	4222-4228	little	_
24-21	4229-4231	as	_
24-22	4232-4240	possible	_
24-23	4241-4242	,	_
24-24	4243-4245	to	_
24-25	4246-4251	think	_
24-26	4252-4254	of	_
24-27	4255-4262	nothing	_
24-28	4263-4265	in	_
24-29	4266-4276	particular	_
24-30	4277-4278	,	_
24-31	4279-4282	and	_
24-32	4283-4286	not	_
24-33	4287-4289	to	_
24-34	4290-4294	fall	_
24-35	4295-4301	asleep	_
24-36	4302-4303	.	_

Text=Definition of the IPL subregions Here, the naming of the IPL subregions was based on previous studies on cytoarchitecture.
25-1	4304-4314	Definition	_
25-2	4315-4317	of	_
25-3	4318-4321	the	_
25-4	4322-4325	IPL	_
25-5	4326-4336	subregions	_
25-6	4337-4341	Here	_
25-7	4342-4343	,	_
25-8	4344-4347	the	_
25-9	4348-4354	naming	_
25-10	4355-4357	of	_
25-11	4358-4361	the	_
25-12	4362-4365	IPL	_
25-13	4366-4376	subregions	_
25-14	4377-4380	was	_
25-15	4381-4386	based	_
25-16	4387-4389	on	_
25-17	4390-4398	previous	_
25-18	4399-4406	studies	_
25-19	4407-4409	on	_
25-20	4410-4426	cytoarchitecture	_
25-21	4427-4428	.	_

Text=The IPL contains PF and PG, where P represents the parietal cortex, PF is the number F subregion of the parietal cortex corresponding to the SMG (BA 40), and PG is the number G subregion of the parietal cortex corresponding to the AG (BA 39).
26-1	4429-4432	The	_
26-2	4433-4436	IPL	_
26-3	4437-4445	contains	_
26-4	4446-4448	PF	_
26-5	4449-4452	and	_
26-6	4453-4455	PG	_
26-7	4456-4457	,	_
26-8	4458-4463	where	_
26-9	4464-4465	P	_
26-10	4466-4476	represents	_
26-11	4477-4480	the	_
26-12	4481-4489	parietal	_
26-13	4490-4496	cortex	_
26-14	4497-4498	,	_
26-15	4499-4501	PF	_
26-16	4502-4504	is	_
26-17	4505-4508	the	_
26-18	4509-4515	number	_
26-19	4516-4517	F	_
26-20	4518-4527	subregion	_
26-21	4528-4530	of	_
26-22	4531-4534	the	_
26-23	4535-4543	parietal	_
26-24	4544-4550	cortex	_
26-25	4551-4564	corresponding	_
26-26	4565-4567	to	_
26-27	4568-4571	the	_
26-28	4572-4575	SMG	_
26-29	4576-4577	(	_
26-30	4578-4580	BA	_
26-31	4581-4583	40	_
26-32	4584-4585	)	_
26-33	4586-4587	,	_
26-34	4588-4591	and	_
26-35	4592-4594	PG	_
26-36	4595-4597	is	_
26-37	4598-4601	the	_
26-38	4602-4608	number	_
26-39	4609-4610	G	_
26-40	4611-4620	subregion	_
26-41	4621-4623	of	_
26-42	4624-4627	the	_
26-43	4628-4636	parietal	_
26-44	4637-4643	cortex	_
26-45	4644-4657	corresponding	_
26-46	4658-4660	to	_
26-47	4661-4664	the	_
26-48	4665-4667	AG	_
26-49	4668-4669	(	_
26-50	4670-4672	BA	_
26-51	4673-4675	39	_
26-52	4676-4677	)	_
26-53	4678-4679	.	_

Text=Based on local variations in cytoarchitecture, four additional subregions are identified in PF: PFop, the opercular part of PF; PFt, the part of PF with a thin cortical ribbon; PFm, the magnocellular part of PF; PFcm, the magnocellular and columnar part of PF, and PG is subdivided into PGa and PGp, representing the anterior and posterior parts of PG, respectively.
27-1	4680-4685	Based	_
27-2	4686-4688	on	_
27-3	4689-4694	local	_
27-4	4695-4705	variations	_
27-5	4706-4708	in	_
27-6	4709-4725	cytoarchitecture	_
27-7	4726-4727	,	_
27-8	4728-4732	four	_
27-9	4733-4743	additional	_
27-10	4744-4754	subregions	_
27-11	4755-4758	are	_
27-12	4759-4769	identified	_
27-13	4770-4772	in	_
27-14	4773-4775	PF	_
27-15	4776-4777	:	_
27-16	4778-4782	PFop	_
27-17	4783-4784	,	_
27-18	4785-4788	the	_
27-19	4789-4798	opercular	_
27-20	4799-4803	part	_
27-21	4804-4806	of	_
27-22	4807-4809	PF	_
27-23	4810-4811	;	_
27-24	4812-4815	PFt	_
27-25	4816-4817	,	_
27-26	4818-4821	the	_
27-27	4822-4826	part	_
27-28	4827-4829	of	_
27-29	4830-4832	PF	_
27-30	4833-4837	with	_
27-31	4838-4839	a	_
27-32	4840-4844	thin	_
27-33	4845-4853	cortical	_
27-34	4854-4860	ribbon	_
27-35	4861-4862	;	_
27-36	4863-4866	PFm	_
27-37	4867-4868	,	_
27-38	4869-4872	the	_
27-39	4873-4886	magnocellular	_
27-40	4887-4891	part	_
27-41	4892-4894	of	_
27-42	4895-4897	PF	_
27-43	4898-4899	;	_
27-44	4900-4904	PFcm	_
27-45	4905-4906	,	_
27-46	4907-4910	the	_
27-47	4911-4924	magnocellular	_
27-48	4925-4928	and	_
27-49	4929-4937	columnar	_
27-50	4938-4942	part	_
27-51	4943-4945	of	_
27-52	4946-4948	PF	_
27-53	4949-4950	,	_
27-54	4951-4954	and	_
27-55	4955-4957	PG	_
27-56	4958-4960	is	_
27-57	4961-4971	subdivided	_
27-58	4972-4976	into	_
27-59	4977-4980	PGa	_
27-60	4981-4984	and	_
27-61	4985-4988	PGp	_
27-62	4989-4990	,	_
27-63	4991-5003	representing	_
27-64	5004-5007	the	_
27-65	5008-5016	anterior	_
27-66	5017-5020	and	_
27-67	5021-5030	posterior	_
27-68	5031-5036	parts	_
27-69	5037-5039	of	_
27-70	5040-5042	PG	_
27-71	5043-5044	,	_
27-72	5045-5057	respectively	_
27-73	5058-5059	.	_

Text=PFm has been named as the transition zone of the IPL because it is located between PF and PG and has common cytoarchitectural features with PF and PG.
28-1	5060-5063	PFm	_
28-2	5064-5067	has	_
28-3	5068-5072	been	_
28-4	5073-5078	named	_
28-5	5079-5081	as	_
28-6	5082-5085	the	_
28-7	5086-5096	transition	_
28-8	5097-5101	zone	_
28-9	5102-5104	of	_
28-10	5105-5108	the	_
28-11	5109-5112	IPL	_
28-12	5113-5120	because	_
28-13	5121-5123	it	_
28-14	5124-5126	is	_
28-15	5127-5134	located	_
28-16	5135-5142	between	_
28-17	5143-5145	PF	_
28-18	5146-5149	and	_
28-19	5150-5152	PG	_
28-20	5153-5156	and	_
28-21	5157-5160	has	_
28-22	5161-5167	common	_
28-23	5168-5185	cytoarchitectural	_
28-24	5186-5194	features	_
28-25	5195-5199	with	_
28-26	5200-5202	PF	_
28-27	5203-5206	and	_
28-28	5207-5209	PG	_
28-29	5210-5211	.	_

Text=The IPL subregions were defined according to a connection-based parcellation study using diffusion MRI data.
29-1	5212-5215	The	_
29-2	5216-5219	IPL	_
29-3	5220-5230	subregions	_
29-4	5231-5235	were	_
29-5	5236-5243	defined	_
29-6	5244-5253	according	_
29-7	5254-5256	to	_
29-8	5257-5258	a	_
29-9	5259-5275	connection-based	_
29-10	5276-5288	parcellation	_
29-11	5289-5294	study	_
29-12	5295-5300	using	_
29-13	5301-5310	diffusion	_
29-14	5311-5314	MRI	_
29-15	5315-5319	data	_
29-16	5320-5321	.	_

Text=As shown in Fig.
30-1	5322-5324	As	_
30-2	5325-5330	shown	_
30-3	5331-5333	in	_
30-4	5334-5337	Fig	_
30-5	5338-5339	.	_

Text=1, the left IPL was parcellated into six subregions including PFt, PFop, PF + PFcm, PFm, PGa and PGp, whereas the right IPL was parcellated into five subregions, i.e., PFop, PF + PFt, PFm, PGa and PGp.
31-1	5340-5341	1	_
31-2	5342-5343	,	_
31-3	5344-5347	the	_
31-4	5348-5352	left	_
31-5	5353-5356	IPL	_
31-6	5357-5360	was	_
31-7	5361-5372	parcellated	_
31-8	5373-5377	into	_
31-9	5378-5381	six	_
31-10	5382-5392	subregions	_
31-11	5393-5402	including	_
31-12	5403-5406	PFt	_
31-13	5407-5408	,	_
31-14	5409-5413	PFop	_
31-15	5414-5415	,	_
31-16	5416-5418	PF	_
31-17	5419-5420	+	_
31-18	5421-5425	PFcm	_
31-19	5426-5427	,	_
31-20	5428-5431	PFm	_
31-21	5432-5433	,	_
31-22	5434-5437	PGa	_
31-23	5438-5441	and	_
31-24	5442-5445	PGp	_
31-25	5446-5447	,	_
31-26	5448-5455	whereas	_
31-27	5456-5459	the	_
31-28	5460-5465	right	_
31-29	5466-5469	IPL	_
31-30	5470-5473	was	_
31-31	5474-5485	parcellated	_
31-32	5486-5490	into	_
31-33	5491-5495	five	_
31-34	5496-5506	subregions	_
31-35	5507-5508	,	_
31-36	5509-5513	i.e.	_
31-37	5514-5515	,	_
31-38	5516-5520	PFop	_
31-39	5521-5522	,	_
31-40	5523-5525	PF	_
31-41	5526-5527	+	_
31-42	5528-5531	PFt	_
31-43	5532-5533	,	_
31-44	5534-5537	PFm	_
31-45	5538-5539	,	_
31-46	5540-5543	PGa	_
31-47	5544-5547	and	_
31-48	5548-5551	PGp	_
31-49	5552-5553	.	_

Text=These subregions have shown their specific rsFC patterns, and thus this parcellation scheme is especially suitable for investigating subregion-specific rsFC changes of the IPL in schizophrenia.
32-1	5554-5559	These	_
32-2	5560-5570	subregions	_
32-3	5571-5575	have	_
32-4	5576-5581	shown	_
32-5	5582-5587	their	_
32-6	5588-5596	specific	_
32-7	5597-5601	rsFC	_
32-8	5602-5610	patterns	_
32-9	5611-5612	,	_
32-10	5613-5616	and	_
32-11	5617-5621	thus	_
32-12	5622-5626	this	_
32-13	5627-5639	parcellation	_
32-14	5640-5646	scheme	_
32-15	5647-5649	is	_
32-16	5650-5660	especially	_
32-17	5661-5669	suitable	_
32-18	5670-5673	for	_
32-19	5674-5687	investigating	_
32-20	5688-5706	subregion-specific	_
32-21	5707-5711	rsFC	_
32-22	5712-5719	changes	_
32-23	5720-5722	of	_
32-24	5723-5726	the	_
32-25	5727-5730	IPL	_
32-26	5731-5733	in	_
32-27	5734-5747	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
32-28	5748-5749	.	_

Text=rs-fMRI Data preprocessing The rs-fMRI data were preprocessed using SPM8.
33-1	5750-5757	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
33-2	5758-5762	Data	_
33-3	5763-5776	preprocessing	_
33-4	5777-5780	The	_
33-5	5781-5788	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
33-6	5789-5793	data	_
33-7	5794-5798	were	_
33-8	5799-5811	preprocessed	_
33-9	5812-5817	using	_
33-10	5818-5822	SPM8	_
33-11	5823-5824	.	_

Text=The first 10 volumes for each subject were discarded to allow the signal to reach equilibrium and the participants to adapt to the scanning noise.
34-1	5825-5828	The	_
34-2	5829-5834	first	_
34-3	5835-5837	10	_
34-4	5838-5845	volumes	_
34-5	5846-5849	for	_
34-6	5850-5854	each	_
34-7	5855-5862	subject	_
34-8	5863-5867	were	_
34-9	5868-5877	discarded	_
34-10	5878-5880	to	_
34-11	5881-5886	allow	_
34-12	5887-5890	the	_
34-13	5891-5897	signal	_
34-14	5898-5900	to	_
34-15	5901-5906	reach	_
34-16	5907-5918	equilibrium	_
34-17	5919-5922	and	_
34-18	5923-5926	the	_
34-19	5927-5939	participants	_
34-20	5940-5942	to	_
34-21	5943-5948	adapt	_
34-22	5949-5951	to	_
34-23	5952-5955	the	_
34-24	5956-5964	scanning	_
34-25	5965-5970	noise	_
34-26	5971-5972	.	_

Text=The remaining volumes were then corrected for the acquisition time delay between slices.
35-1	5973-5976	The	_
35-2	5977-5986	remaining	_
35-3	5987-5994	volumes	_
35-4	5995-5999	were	_
35-5	6000-6004	then	_
35-6	6005-6014	corrected	_
35-7	6015-6018	for	_
35-8	6019-6022	the	_
35-9	6023-6034	acquisition	_
35-10	6035-6039	time	_
35-11	6040-6045	delay	_
35-12	6046-6053	between	_
35-13	6054-6060	slices	_
35-14	6061-6062	.	_

Text=On the basis of head motion, seven patients' fMRI data were excluded from further analysis because their translational or rotational motion parameters were greater than 2 mm or 2°.
36-1	6063-6065	On	_
36-2	6066-6069	the	_
36-3	6070-6075	basis	_
36-4	6076-6078	of	_
36-5	6079-6083	head	_
36-6	6084-6090	motion	_
36-7	6091-6092	,	_
36-8	6093-6098	seven	_
36-9	6099-6107	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
36-10	6108-6109	'	_
36-11	6110-6114	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
36-12	6115-6119	data	_
36-13	6120-6124	were	_
36-14	6125-6133	excluded	_
36-15	6134-6138	from	_
36-16	6139-6146	further	_
36-17	6147-6155	analysis	_
36-18	6156-6163	because	_
36-19	6164-6169	their	_
36-20	6170-6183	translational	_
36-21	6184-6186	or	_
36-22	6187-6197	rotational	_
36-23	6198-6204	motion	_
36-24	6205-6215	parameters	_
36-25	6216-6220	were	_
36-26	6221-6228	greater	_
36-27	6229-6233	than	_
36-28	6234-6235	2	_
36-29	6236-6238	mm	_
36-30	6239-6241	or	_
36-31	6242-6244	2°	_
36-32	6245-6246	.	_

Text=We also calculated framewise displacement (FD), which indexes volume-to-volume changes in head position.
37-1	6247-6249	We	_
37-2	6250-6254	also	_
37-3	6255-6265	calculated	_
37-4	6266-6275	framewise	_
37-5	6276-6288	displacement	_
37-6	6289-6290	(	_
37-7	6291-6293	FD	_
37-8	6294-6295	)	_
37-9	6296-6297	,	_
37-10	6298-6303	which	_
37-11	6304-6311	indexes	_
37-12	6312-6328	volume-to-volume	_
37-13	6329-6336	changes	_
37-14	6337-6339	in	_
37-15	6340-6344	head	_
37-16	6345-6353	position	_
37-17	6354-6355	.	_

Text=Because recent studies have reported that signal spike caused by head motion significantly contaminated the final rs-fMRI results even after regressing out the realignment parameters, we removed spike volumes with the FD> 0.5.
38-1	6356-6363	Because	_
38-2	6364-6370	recent	_
38-3	6371-6378	studies	_
38-4	6379-6383	have	_
38-5	6384-6392	reported	_
38-6	6393-6397	that	_
38-7	6398-6404	signal	_
38-8	6405-6410	spike	_
38-9	6411-6417	caused	_
38-10	6418-6420	by	_
38-11	6421-6425	head	_
38-12	6426-6432	motion	_
38-13	6433-6446	significantly	_
38-14	6447-6459	contaminated	_
38-15	6460-6463	the	_
38-16	6464-6469	final	_
38-17	6470-6477	rs-fMRI	_
38-18	6478-6485	results	_
38-19	6486-6490	even	_
38-20	6491-6496	after	_
38-21	6497-6507	regressing	_
38-22	6508-6511	out	_
38-23	6512-6515	the	_
38-24	6516-6527	realignment	_
38-25	6528-6538	parameters	_
38-26	6539-6540	,	_
38-27	6541-6543	we	_
38-28	6544-6551	removed	_
38-29	6552-6557	spike	_
38-30	6558-6565	volumes	_
38-31	6566-6570	with	_
38-32	6571-6574	the	_
38-33	6575-6577	FD	_
38-34	6578-6579	>	_
38-35	6580-6583	0.5	_
38-36	6584-6585	.	_

Text=Several nuisance covariates (six motion parameters and average BOLD signals of the ventricular and white matter) were regressed out from the data.
39-1	6586-6593	Several	_
39-2	6594-6602	nuisance	_
39-3	6603-6613	covariates	_
39-4	6614-6615	(	_
39-5	6616-6619	six	_
39-6	6620-6626	motion	_
39-7	6627-6637	parameters	_
39-8	6638-6641	and	_
39-9	6642-6649	average	_
39-10	6650-6654	BOLD	_
39-11	6655-6662	signals	_
39-12	6663-6665	of	_
39-13	6666-6669	the	_
39-14	6670-6681	ventricular	_
39-15	6682-6685	and	_
39-16	6686-6691	white	_
39-17	6692-6698	matter	_
39-18	6699-6700	)	_
39-19	6701-6705	were	_
39-20	6706-6715	regressed	_
39-21	6716-6719	out	_
39-22	6720-6724	from	_
39-23	6725-6728	the	_
39-24	6729-6733	data	_
39-25	6734-6735	.	_

Text=The datasets were band-pass filtered with a frequency range of 0.01 to 0.08 Hz to reduce low-frequency drift and high-frequency noise.
40-1	6736-6739	The	_
40-2	6740-6748	datasets	_
40-3	6749-6753	were	_
40-4	6754-6763	band-pass	_
40-5	6764-6772	filtered	_
40-6	6773-6777	with	_
40-7	6778-6779	a	_
40-8	6780-6789	frequency	_
40-9	6790-6795	range	_
40-10	6796-6798	of	_
40-11	6799-6803	0.01	_
40-12	6804-6806	to	_
40-13	6807-6811	0.08	_
40-14	6812-6814	Hz	_
40-15	6815-6817	to	_
40-16	6818-6824	reduce	_
40-17	6825-6838	low-frequency	_
40-18	6839-6844	drift	_
40-19	6845-6848	and	_
40-20	6849-6863	high-frequency	_
40-21	6864-6869	noise	_
40-22	6870-6871	.	_

Text=Individual structural images were linearly coregistered to the mean functional image; then, the transformed structural images were segmented into GM, white matter, and cerebrospinal fluid.
41-1	6872-6882	Individual	_
41-2	6883-6893	structural	_
41-3	6894-6900	images	_
41-4	6901-6905	were	_
41-5	6906-6914	linearly	_
41-6	6915-6927	coregistered	_
41-7	6928-6930	to	_
41-8	6931-6934	the	_
41-9	6935-6939	mean	_
41-10	6940-6950	functional	_
41-11	6951-6956	image	_
41-12	6957-6958	;	_
41-13	6959-6963	then	_
41-14	6964-6965	,	_
41-15	6966-6969	the	_
41-16	6970-6981	transformed	_
41-17	6982-6992	structural	_
41-18	6993-6999	images	_
41-19	7000-7004	were	_
41-20	7005-7014	segmented	_
41-21	7015-7019	into	_
41-22	7020-7022	GM	_
41-23	7023-7024	,	_
41-24	7025-7030	white	_
41-25	7031-7037	matter	_
41-26	7038-7039	,	_
41-27	7040-7043	and	_
41-28	7044-7057	cerebrospinal	_
41-29	7058-7063	fluid	_
41-30	7064-7065	.	_

Text=The GM maps were linearly coregistered to the tissue probability maps in the Montreal Neurological Institute (MNI) space.
42-1	7066-7069	The	_
42-2	7070-7072	GM	_
42-3	7073-7077	maps	_
42-4	7078-7082	were	_
42-5	7083-7091	linearly	_
42-6	7092-7104	coregistered	_
42-7	7105-7107	to	_
42-8	7108-7111	the	_
42-9	7112-7118	tissue	_
42-10	7119-7130	probability	_
42-11	7131-7135	maps	_
42-12	7136-7138	in	_
42-13	7139-7142	the	_
42-14	7143-7151	Montreal	_
42-15	7152-7164	Neurological	_
42-16	7165-7174	Institute	_
42-17	7175-7176	(	_
42-18	7177-7180	MNI	_
42-19	7181-7182	)	_
42-20	7183-7188	space	_
42-21	7189-7190	.	_

Text=Finally the motion-corrected functional volumes were spatially normalized to the MNI space using the parameters estimated during linear coregistration.
43-1	7191-7198	Finally	_
43-2	7199-7202	the	_
43-3	7203-7219	motion-corrected	_
43-4	7220-7230	functional	_
43-5	7231-7238	volumes	_
43-6	7239-7243	were	_
43-7	7244-7253	spatially	_
43-8	7254-7264	normalized	_
43-9	7265-7267	to	_
43-10	7268-7271	the	_
43-11	7272-7275	MNI	_
43-12	7276-7281	space	_
43-13	7282-7287	using	_
43-14	7288-7291	the	_
43-15	7292-7302	parameters	_
43-16	7303-7312	estimated	_
43-17	7313-7319	during	_
43-18	7320-7326	linear	_
43-19	7327-7341	coregistration	_
43-20	7342-7343	.	_

Text=The functional images were resampled into a 3 × 3 × 3 mm3 voxel.
44-1	7344-7347	The	_
44-2	7348-7358	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
44-3	7359-7365	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
44-4	7366-7370	were	_
44-5	7371-7380	resampled	_
44-6	7381-7385	into	_
44-7	7386-7387	a	_
44-8	7388-7389	3	_
44-9	7390-7391	×	_
44-10	7392-7393	3	_
44-11	7394-7395	×	_
44-12	7396-7397	3	_
44-13	7398-7401	mm3	_
44-14	7402-7407	voxel	_
44-15	7408-7409	.	_

Text=After normalization, all datasets were smoothed with a Gaussian kernel of 6 × 6 × 6 mm3 full-width at half maximum.
45-1	7410-7415	After	_
45-2	7416-7429	normalization	_
45-3	7430-7431	,	_
45-4	7432-7435	all	_
45-5	7436-7444	datasets	_
45-6	7445-7449	were	_
45-7	7450-7458	smoothed	_
45-8	7459-7463	with	_
45-9	7464-7465	a	_
45-10	7466-7474	Gaussian	_
45-11	7475-7481	kernel	_
45-12	7482-7484	of	_
45-13	7485-7486	6	_
45-14	7487-7488	×	_
45-15	7489-7490	6	_
45-16	7491-7492	×	_
45-17	7493-7494	6	_
45-18	7495-7498	mm3	_
45-19	7499-7509	full-width	_
45-20	7510-7512	at	_
45-21	7513-7517	half	_
45-22	7518-7525	maximum	_
45-23	7526-7527	.	_

Text=rsFC Analysis For individual datasets, Pearson's correlation coefficients between the mean timecourses of each IPL subregion and timecourses of each voxel in other parts of the brain grey matter were computed and converted to z values using Fisher's r-to-z transformation to improve the normality.
46-1	7528-7532	rsFC	_
46-2	7533-7541	Analysis	_
46-3	7542-7545	For	_
46-4	7546-7556	individual	_
46-5	7557-7565	datasets	_
46-6	7566-7567	,	_
46-7	7568-7575	Pearson	_
46-8	7576-7578	's	_
46-9	7579-7590	correlation	_
46-10	7591-7603	coefficients	_
46-11	7604-7611	between	_
46-12	7612-7615	the	_
46-13	7616-7620	mean	_
46-14	7621-7632	timecourses	_
46-15	7633-7635	of	_
46-16	7636-7640	each	_
46-17	7641-7644	IPL	_
46-18	7645-7654	subregion	_
46-19	7655-7658	and	_
46-20	7659-7670	timecourses	_
46-21	7671-7673	of	_
46-22	7674-7678	each	_
46-23	7679-7684	voxel	_
46-24	7685-7687	in	_
46-25	7688-7693	other	_
46-26	7694-7699	parts	_
46-27	7700-7702	of	_
46-28	7703-7706	the	_
46-29	7707-7712	brain	_
46-30	7713-7717	grey	_
46-31	7718-7724	matter	_
46-32	7725-7729	were	_
46-33	7730-7738	computed	_
46-34	7739-7742	and	_
46-35	7743-7752	converted	_
46-36	7753-7755	to	_
46-37	7756-7757	z	_
46-38	7758-7764	values	_
46-39	7765-7770	using	_
46-40	7771-7777	Fisher	_
46-41	7778-7780	's	_
46-42	7781-7787	r-to-z	_
46-43	7788-7802	transformation	_
46-44	7803-7805	to	_
46-45	7806-7813	improve	_
46-46	7814-7817	the	_
46-47	7818-7827	normality	_
46-48	7828-7829	.	_

Text=For each group, individuals' z values were then entered into a random-effect one-sample t-test in a voxel-wise manner to identify brain regions that showed significant positive correlations with each IPL subregion.
47-1	7830-7833	For	_
47-2	7834-7838	each	_
47-3	7839-7844	group	_
47-4	7845-7846	,	_
47-5	7847-7858	individuals	_
47-6	7859-7860	'	_
47-7	7861-7862	z	_
47-8	7863-7869	values	_
47-9	7870-7874	were	_
47-10	7875-7879	then	_
47-11	7880-7887	entered	_
47-12	7888-7892	into	_
47-13	7893-7894	a	_
47-14	7895-7908	random-effect	_
47-15	7909-7919	one-sample	_
47-16	7920-7926	t-test	_
47-17	7927-7929	in	_
47-18	7930-7931	a	_
47-19	7932-7942	voxel-wise	_
47-20	7943-7949	manner	_
47-21	7950-7952	to	_
47-22	7953-7961	identify	_
47-23	7962-7967	brain	_
47-24	7968-7975	regions	_
47-25	7976-7980	that	_
47-26	7981-7987	showed	_
47-27	7988-7999	significant	_
47-28	8000-8008	positive	_
47-29	8009-8021	correlations	_
47-30	8022-8026	with	_
47-31	8027-8031	each	_
47-32	8032-8035	IPL	_
47-33	8036-8045	subregion	_
47-34	8046-8047	.	_

Text=Then for each IPL subregion, voxels that showed significant positive correlations with the subregion in any of the two groups were merged into a mask.
48-1	8048-8052	Then	_
48-2	8053-8056	for	_
48-3	8057-8061	each	_
48-4	8062-8065	IPL	_
48-5	8066-8075	subregion	_
48-6	8076-8077	,	_
48-7	8078-8084	voxels	_
48-8	8085-8089	that	_
48-9	8090-8096	showed	_
48-10	8097-8108	significant	_
48-11	8109-8117	positive	_
48-12	8118-8130	correlations	_
48-13	8131-8135	with	_
48-14	8136-8139	the	_
48-15	8140-8149	subregion	_
48-16	8150-8152	in	_
48-17	8153-8156	any	_
48-18	8157-8159	of	_
48-19	8160-8163	the	_
48-20	8164-8167	two	_
48-21	8168-8174	groups	_
48-22	8175-8179	were	_
48-23	8180-8186	merged	_
48-24	8187-8191	into	_
48-25	8192-8193	a	_
48-26	8194-8198	mask	_
48-27	8199-8200	.	_

Text=Then, general linear model was performed within the mask of each IPL subregion to quantitatively compare intergroup differences in rsFC of this IPL subregion while controlling for the effects of age and gender.
49-1	8201-8205	Then	_
49-2	8206-8207	,	_
49-3	8208-8215	general	_
49-4	8216-8222	linear	_
49-5	8223-8228	model	_
49-6	8229-8232	was	_
49-7	8233-8242	performed	_
49-8	8243-8249	within	_
49-9	8250-8253	the	_
49-10	8254-8258	mask	_
49-11	8259-8261	of	_
49-12	8262-8266	each	_
49-13	8267-8270	IPL	_
49-14	8271-8280	subregion	_
49-15	8281-8283	to	_
49-16	8284-8298	quantitatively	_
49-17	8299-8306	compare	_
49-18	8307-8317	intergroup	_
49-19	8318-8329	differences	_
49-20	8330-8332	in	_
49-21	8333-8337	rsFC	_
49-22	8338-8340	of	_
49-23	8341-8345	this	_
49-24	8346-8349	IPL	_
49-25	8350-8359	subregion	_
49-26	8360-8365	while	_
49-27	8366-8377	controlling	_
49-28	8378-8381	for	_
49-29	8382-8385	the	_
49-30	8386-8393	effects	_
49-31	8394-8396	of	_
49-32	8397-8400	age	_
49-33	8401-8404	and	_
49-34	8405-8411	gender	_
49-35	8412-8413	.	_

Text=Because several previous studies reported decreased GMV in the IPL in schizophrenia, we also added the GMV of each subregion as an additional covariate of no interest in the rsFC analyses of the IPL subregions.
50-1	8414-8421	Because	_
50-2	8422-8429	several	_
50-3	8430-8438	previous	_
50-4	8439-8446	studies	_
50-5	8447-8455	reported	_
50-6	8456-8465	decreased	_
50-7	8466-8469	GMV	_
50-8	8470-8472	in	_
50-9	8473-8476	the	_
50-10	8477-8480	IPL	_
50-11	8481-8483	in	_
50-12	8484-8497	schizophrenia	_
50-13	8498-8499	,	_
50-14	8500-8502	we	_
50-15	8503-8507	also	_
50-16	8508-8513	added	_
50-17	8514-8517	the	_
50-18	8518-8521	GMV	_
50-19	8522-8524	of	_
50-20	8525-8529	each	_
50-21	8530-8539	subregion	_
50-22	8540-8542	as	_
50-23	8543-8545	an	_
50-24	8546-8556	additional	_
50-25	8557-8566	covariate	_
50-26	8567-8569	of	_
50-27	8570-8572	no	_
50-28	8573-8581	interest	_
50-29	8582-8584	in	_
50-30	8585-8588	the	_
50-31	8589-8593	rsFC	_
50-32	8594-8602	analyses	_
50-33	8603-8605	of	_
50-34	8606-8609	the	_
50-35	8610-8613	IPL	_
50-36	8614-8624	subregions	_
50-37	8625-8626	.	_

Text=The detailed description of GMV calculation is shown in the Supplementary materials.
51-1	8627-8630	The	_
51-2	8631-8639	detailed	_
51-3	8640-8651	description	_
51-4	8652-8654	of	_
51-5	8655-8658	GMV	_
51-6	8659-8670	calculation	_
51-7	8671-8673	is	_
51-8	8674-8679	shown	_
51-9	8680-8682	in	_
51-10	8683-8686	the	_
51-11	8687-8700	Supplementary	_
51-12	8701-8710	materials	_
51-13	8711-8712	.	_

Text=Multiple comparisons for these rsFC analyses were corrected using the false discovery rate (FDR) method.
52-1	8713-8721	Multiple	_
52-2	8722-8733	comparisons	_
52-3	8734-8737	for	_
52-4	8738-8743	these	_
52-5	8744-8748	rsFC	_
52-6	8749-8757	analyses	_
52-7	8758-8762	were	_
52-8	8763-8772	corrected	_
52-9	8773-8778	using	_
52-10	8779-8782	the	_
52-11	8783-8788	false	_
52-12	8789-8798	discovery	_
52-13	8799-8803	rate	_
52-14	8804-8805	(	_
52-15	8806-8809	FDR	_
52-16	8810-8811	)	_
52-17	8812-8818	method	_
52-18	8819-8820	.	_

Text=Because 11 regions were analyzed, we further controlled for these additional comparisons using a corrected threshold of P <0.05/11 = 0.0045 (FDR corrected, two-tailed).
53-1	8821-8828	Because	_
53-2	8829-8831	11	_
53-3	8832-8839	regions	_
53-4	8840-8844	were	_
53-5	8845-8853	analyzed	_
53-6	8854-8855	,	_
53-7	8856-8858	we	_
53-8	8859-8866	further	_
53-9	8867-8877	controlled	_
53-10	8878-8881	for	_
53-11	8882-8887	these	_
53-12	8888-8898	additional	_
53-13	8899-8910	comparisons	_
53-14	8911-8916	using	_
53-15	8917-8918	a	_
53-16	8919-8928	corrected	_
53-17	8929-8938	threshold	_
53-18	8939-8941	of	_
53-19	8942-8943	P	_
53-20	8944-8945	<	_
53-21	8946-8953	0.05/11	_
53-22	8954-8955	=	_
53-23	8956-8962	0.0045	_
53-24	8963-8964	(	_
53-25	8965-8968	FDR	_
53-26	8969-8978	corrected	_
53-27	8979-8980	,	_
53-28	8981-8991	two-tailed	_
53-29	8992-8993	)	_
53-30	8994-8995	.	_

Text=Moreover, we also used a relatively lenient threshold (FDR corrected, P <0.01, two-tailed) to reduce type II error.
54-1	8996-9004	Moreover	_
54-2	9005-9006	,	_
54-3	9007-9009	we	_
54-4	9010-9014	also	_
54-5	9015-9019	used	_
54-6	9020-9021	a	_
54-7	9022-9032	relatively	_
54-8	9033-9040	lenient	_
54-9	9041-9050	threshold	_
54-10	9051-9052	(	_
54-11	9053-9056	FDR	_
54-12	9057-9066	corrected	_
54-13	9067-9068	,	_
54-14	9069-9070	P	_
54-15	9071-9072	<	_
54-16	9073-9077	0.01	_
54-17	9078-9079	,	_
54-18	9080-9090	two-tailed	_
54-19	9091-9092	)	_
54-20	9093-9095	to	_
54-21	9096-9102	reduce	_
54-22	9103-9107	type	_
54-23	9108-9110	II	_
54-24	9111-9116	error	_
54-25	9117-9118	.	_

Text=Validation analysis To test whether the resulted rsFC map of each IPL subregion reflects its own unique variance, we recalculated rsFC maps using one first-level model per subject including the preprocessed BOLD timecourses of all IPL subregions.
55-1	9119-9129	Validation	_
55-2	9130-9138	analysis	_
55-3	9139-9141	To	_
55-4	9142-9146	test	_
55-5	9147-9154	whether	_
55-6	9155-9158	the	_
55-7	9159-9167	resulted	_
55-8	9168-9172	rsFC	_
55-9	9173-9176	map	_
55-10	9177-9179	of	_
55-11	9180-9184	each	_
55-12	9185-9188	IPL	_
55-13	9189-9198	subregion	_
55-14	9199-9207	reflects	_
55-15	9208-9211	its	_
55-16	9212-9215	own	_
55-17	9216-9222	unique	_
55-18	9223-9231	variance	_
55-19	9232-9233	,	_
55-20	9234-9236	we	_
55-21	9237-9249	recalculated	_
55-22	9250-9254	rsFC	_
55-23	9255-9259	maps	_
55-24	9260-9265	using	_
55-25	9266-9269	one	_
55-26	9270-9281	first-level	_
55-27	9282-9287	model	_
55-28	9288-9291	per	_
55-29	9292-9299	subject	_
55-30	9300-9309	including	_
55-31	9310-9313	the	_
55-32	9314-9326	preprocessed	_
55-33	9327-9331	BOLD	_
55-34	9332-9343	timecourses	_
55-35	9344-9346	of	_
55-36	9347-9350	all	_
55-37	9351-9354	IPL	_
55-38	9355-9365	subregions	_
55-39	9366-9367	.	_

Text=For each hemisphere of each subject, the timecourses of each IPL subregion was orthogonalized with respect to each of the other IPL subregions using the Gram-Schmidt process, to ensure that the timecourses for each IPL subregion reflected its unique variance.
56-1	9368-9371	For	_
56-2	9372-9376	each	_
56-3	9377-9387	hemisphere	_
56-4	9388-9390	of	_
56-5	9391-9395	each	_
56-6	9396-9403	subject	_
56-7	9404-9405	,	_
56-8	9406-9409	the	_
56-9	9410-9421	timecourses	_
56-10	9422-9424	of	_
56-11	9425-9429	each	_
56-12	9430-9433	IPL	_
56-13	9434-9443	subregion	_
56-14	9444-9447	was	_
56-15	9448-9462	orthogonalized	_
56-16	9463-9467	with	_
56-17	9468-9475	respect	_
56-18	9476-9478	to	_
56-19	9479-9483	each	_
56-20	9484-9486	of	_
56-21	9487-9490	the	_
56-22	9491-9496	other	_
56-23	9497-9500	IPL	_
56-24	9501-9511	subregions	_
56-25	9512-9517	using	_
56-26	9518-9521	the	_
56-27	9522-9534	Gram-Schmidt	_
56-28	9535-9542	process	_
56-29	9543-9544	,	_
56-30	9545-9547	to	_
56-31	9548-9554	ensure	_
56-32	9555-9559	that	_
56-33	9560-9563	the	_
56-34	9564-9575	timecourses	_
56-35	9576-9579	for	_
56-36	9580-9584	each	_
56-37	9585-9588	IPL	_
56-38	9589-9598	subregion	_
56-39	9599-9608	reflected	_
56-40	9609-9612	its	_
56-41	9613-9619	unique	_
56-42	9620-9628	variance	_
56-43	9629-9630	.	_

Text=And then the orthogonalized timecourses of all IPL subregions in the same hemisphere were considered as independent predictors in one multiple regression model to calculate the functional connectivity (i.e., the beta value of the timecourses) between each IPL subregion and each of other voxels of the whole brain, which simultaneously generated the rsFC maps of all IPL subregions in a subject.
57-1	9631-9634	And	_
57-2	9635-9639	then	_
57-3	9640-9643	the	_
57-4	9644-9658	orthogonalized	_
57-5	9659-9670	timecourses	_
57-6	9671-9673	of	_
57-7	9674-9677	all	_
57-8	9678-9681	IPL	_
57-9	9682-9692	subregions	_
57-10	9693-9695	in	_
57-11	9696-9699	the	_
57-12	9700-9704	same	_
57-13	9705-9715	hemisphere	_
57-14	9716-9720	were	_
57-15	9721-9731	considered	_
57-16	9732-9734	as	_
57-17	9735-9746	independent	_
57-18	9747-9757	predictors	_
57-19	9758-9760	in	_
57-20	9761-9764	one	_
57-21	9765-9773	multiple	_
57-22	9774-9784	regression	_
57-23	9785-9790	model	_
57-24	9791-9793	to	_
57-25	9794-9803	calculate	_
57-26	9804-9807	the	_
57-27	9808-9818	functional	_
57-28	9819-9831	connectivity	_
57-29	9832-9833	(	_
57-30	9834-9838	i.e.	_
57-31	9839-9840	,	_
57-32	9841-9844	the	_
57-33	9845-9849	beta	_
57-34	9850-9855	value	_
57-35	9856-9858	of	_
57-36	9859-9862	the	_
57-37	9863-9874	timecourses	_
57-38	9875-9876	)	_
57-39	9877-9884	between	_
57-40	9885-9889	each	_
57-41	9890-9893	IPL	_
57-42	9894-9903	subregion	_
57-43	9904-9907	and	_
57-44	9908-9912	each	_
57-45	9913-9915	of	_
57-46	9916-9921	other	_
57-47	9922-9928	voxels	_
57-48	9929-9931	of	_
57-49	9932-9935	the	_
57-50	9936-9941	whole	_
57-51	9942-9947	brain	_
57-52	9948-9949	,	_
57-53	9950-9955	which	_
57-54	9956-9970	simultaneously	_
57-55	9971-9980	generated	_
57-56	9981-9984	the	_
57-57	9985-9989	rsFC	_
57-58	9990-9994	maps	_
57-59	9995-9997	of	_
57-60	9998-10001	all	_
57-61	10002-10005	IPL	_
57-62	10006-10016	subregions	_
57-63	10017-10019	in	_
57-64	10020-10021	a	_
57-65	10022-10029	subject	_
57-66	10030-10031	.	_

Text=Because global signal regression is still controversial, the global signal was not regressed out from the data.
58-1	10032-10039	Because	_
58-2	10040-10046	global	_
58-3	10047-10053	signal	_
58-4	10054-10064	regression	_
58-5	10065-10067	is	_
58-6	10068-10073	still	_
58-7	10074-10087	controversial	_
58-8	10088-10089	,	_
58-9	10090-10093	the	_
58-10	10094-10100	global	_
58-11	10101-10107	signal	_
58-12	10108-10111	was	_
58-13	10112-10115	not	_
58-14	10116-10125	regressed	_
58-15	10126-10129	out	_
58-16	10130-10134	from	_
58-17	10135-10138	the	_
58-18	10139-10143	data	_
58-19	10144-10145	.	_

Text=The rsFC map of each IPL subregion in each group was calculated using general linear model based on the rsFC map of this subregion in each subject (FDR corrected, P <0.01, two-tailed).
59-1	10146-10149	The	_
59-2	10150-10154	rsFC	_
59-3	10155-10158	map	_
59-4	10159-10161	of	_
59-5	10162-10166	each	_
59-6	10167-10170	IPL	_
59-7	10171-10180	subregion	_
59-8	10181-10183	in	_
59-9	10184-10188	each	_
59-10	10189-10194	group	_
59-11	10195-10198	was	_
59-12	10199-10209	calculated	_
59-13	10210-10215	using	_
59-14	10216-10223	general	_
59-15	10224-10230	linear	_
59-16	10231-10236	model	_
59-17	10237-10242	based	_
59-18	10243-10245	on	_
59-19	10246-10249	the	_
59-20	10250-10254	rsFC	_
59-21	10255-10258	map	_
59-22	10259-10261	of	_
59-23	10262-10266	this	_
59-24	10267-10276	subregion	_
59-25	10277-10279	in	_
59-26	10280-10284	each	_
59-27	10285-10292	subject	_
59-28	10293-10294	(	_
59-29	10295-10298	FDR	_
59-30	10299-10308	corrected	_
59-31	10309-10310	,	_
59-32	10311-10312	P	_
59-33	10313-10314	<	_
59-34	10315-10319	0.01	_
59-35	10320-10321	,	_
59-36	10322-10332	two-tailed	_
59-37	10333-10334	)	_
59-38	10335-10336	.	_

Text=We defined the positive rsFC map of each IPL subregion of each group derived from multiple first-level models with each investigating one region's connectivity as Mask A and that derived from one first-level model per subject as Mask B.
60-1	10337-10339	We	_
60-2	10340-10347	defined	_
60-3	10348-10351	the	_
60-4	10352-10360	positive	_
60-5	10361-10365	rsFC	_
60-6	10366-10369	map	_
60-7	10370-10372	of	_
60-8	10373-10377	each	_
60-9	10378-10381	IPL	_
60-10	10382-10391	subregion	_
60-11	10392-10394	of	_
60-12	10395-10399	each	_
60-13	10400-10405	group	_
60-14	10406-10413	derived	_
60-15	10414-10418	from	_
60-16	10419-10427	multiple	_
60-17	10428-10439	first-level	_
60-18	10440-10446	models	_
60-19	10447-10451	with	_
60-20	10452-10456	each	_
60-21	10457-10470	investigating	_
60-22	10471-10474	one	_
60-23	10475-10481	region	_
60-24	10482-10484	's	_
60-25	10485-10497	connectivity	_
60-26	10498-10500	as	_
60-27	10501-10505	Mask	_
60-28	10506-10507	A	_
60-29	10508-10511	and	_
60-30	10512-10516	that	_
60-31	10517-10524	derived	_
60-32	10525-10529	from	_
60-33	10530-10533	one	_
60-34	10534-10545	first-level	_
60-35	10546-10551	model	_
60-36	10552-10555	per	_
60-37	10556-10563	subject	_
60-38	10564-10566	as	_
60-39	10567-10571	Mask	_
60-40	10572-10573	B	_
60-41	10574-10575	.	_

Text=For each IPL subregion of each group, we projected the Mask A onto the Mask B to compare the spatial differences between the group-level rsFC maps of each IPL subregion derived from the two methods.
61-1	10576-10579	For	_
61-2	10580-10584	each	_
61-3	10585-10588	IPL	_
61-4	10589-10598	subregion	_
61-5	10599-10601	of	_
61-6	10602-10606	each	_
61-7	10607-10612	group	_
61-8	10613-10614	,	_
61-9	10615-10617	we	_
61-10	10618-10627	projected	_
61-11	10628-10631	the	_
61-12	10632-10636	Mask	_
61-13	10637-10638	A	_
61-14	10639-10643	onto	_
61-15	10644-10647	the	_
61-16	10648-10652	Mask	_
61-17	10653-10654	B	_
61-18	10655-10657	to	_
61-19	10658-10665	compare	_
61-20	10666-10669	the	_
61-21	10670-10677	spatial	_
61-22	10678-10689	differences	_
61-23	10690-10697	between	_
61-24	10698-10701	the	_
61-25	10702-10713	group-level	_
61-26	10714-10718	rsFC	_
61-27	10719-10723	maps	_
61-28	10724-10726	of	_
61-29	10727-10731	each	_
61-30	10732-10735	IPL	_
61-31	10736-10745	subregion	_
61-32	10746-10753	derived	_
61-33	10754-10758	from	_
61-34	10759-10762	the	_
61-35	10763-10766	two	_
61-36	10767-10774	methods	_
61-37	10775-10776	.	_

Text=The spatial overlapping ratios of the rsFC maps of each IPL subregion derived from the two methods were calculated by the following equation: Overlapping ratio = (Mask A ∩ Mask B) / (Mask A ∪ Mask B).
62-1	10777-10780	The	_
62-2	10781-10788	spatial	_
62-3	10789-10800	overlapping	_
62-4	10801-10807	ratios	_
62-5	10808-10810	of	_
62-6	10811-10814	the	_
62-7	10815-10819	rsFC	_
62-8	10820-10824	maps	_
62-9	10825-10827	of	_
62-10	10828-10832	each	_
62-11	10833-10836	IPL	_
62-12	10837-10846	subregion	_
62-13	10847-10854	derived	_
62-14	10855-10859	from	_
62-15	10860-10863	the	_
62-16	10864-10867	two	_
62-17	10868-10875	methods	_
62-18	10876-10880	were	_
62-19	10881-10891	calculated	_
62-20	10892-10894	by	_
62-21	10895-10898	the	_
62-22	10899-10908	following	_
62-23	10909-10917	equation	_
62-24	10918-10919	:	_
62-25	10920-10931	Overlapping	_
62-26	10932-10937	ratio	_
62-27	10938-10939	=	_
62-28	10940-10941	(	_
62-29	10942-10946	Mask	_
62-30	10947-10948	A	_
62-31	10949-10950	∩	_
62-32	10951-10955	Mask	_
62-33	10956-10957	B	_
62-34	10958-10959	)	_
62-35	10960-10961	/	_
62-36	10962-10963	(	_
62-37	10964-10968	Mask	_
62-38	10969-10970	A	_
62-39	10971-10972	∪	_
62-40	10973-10977	Mask	_
62-41	10978-10979	B	_
62-42	10980-10981	)	_
62-43	10982-10983	.	_

Text=Effect of antipsychotic treatments on rsFC changes in schizophrenia Although most schizophrenia patients (n = 86) have received antipsychotic treatments, there were drug naïve patients (n = 9).
63-1	10984-10990	Effect	_
63-2	10991-10993	of	_
63-3	10994-11007	antipsychotic	_
63-4	11008-11018	treatments	_
63-5	11019-11021	on	_
63-6	11022-11026	rsFC	_
63-7	11027-11034	changes	_
63-8	11035-11037	in	_
63-9	11038-11051	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
63-10	11052-11060	Although	_
63-11	11061-11065	most	_
63-12	11066-11079	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
63-13	11080-11088	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
63-14	11089-11090	(	_
63-15	11091-11092	n	_
63-16	11093-11094	=	_
63-17	11095-11097	86	_
63-18	11098-11099	)	_
63-19	11100-11104	have	_
63-20	11105-11113	received	_
63-21	11114-11127	antipsychotic	_
63-22	11128-11138	treatments	_
63-23	11139-11140	,	_
63-24	11141-11146	there	_
63-25	11147-11151	were	_
63-26	11152-11156	drug	_
63-27	11157-11162	naïve	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
63-28	11163-11171	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
63-29	11172-11173	(	_
63-30	11174-11175	n	_
63-31	11176-11177	=	_
63-32	11178-11179	9	_
63-33	11180-11181	)	_
63-34	11182-11183	.	_

Text=To explore the effect of antipsychotic treatments on rsFC changes in schizophrenia, we extracted rsFCs of the IPL subregions exhibiting significant intergroup difference from each patient and used two sample t-test to compare these rsFCs between the 9 drug-naïve patients and the 86 patients with antipsychotic treatments (P <0.05, uncorrected).
64-1	11184-11186	To	_
64-2	11187-11194	explore	_
64-3	11195-11198	the	_
64-4	11199-11205	effect	_
64-5	11206-11208	of	_
64-6	11209-11222	antipsychotic	_
64-7	11223-11233	treatments	_
64-8	11234-11236	on	_
64-9	11237-11241	rsFC	_
64-10	11242-11249	changes	_
64-11	11250-11252	in	_
64-12	11253-11266	schizophrenia	_
64-13	11267-11268	,	_
64-14	11269-11271	we	_
64-15	11272-11281	extracted	_
64-16	11282-11287	rsFCs	_
64-17	11288-11290	of	_
64-18	11291-11294	the	_
64-19	11295-11298	IPL	_
64-20	11299-11309	subregions	_
64-21	11310-11320	exhibiting	_
64-22	11321-11332	significant	_
64-23	11333-11343	intergroup	_
64-24	11344-11354	difference	_
64-25	11355-11359	from	_
64-26	11360-11364	each	_
64-27	11365-11372	patient	_
64-28	11373-11376	and	_
64-29	11377-11381	used	_
64-30	11382-11385	two	_
64-31	11386-11392	sample	_
64-32	11393-11399	t-test	_
64-33	11400-11402	to	_
64-34	11403-11410	compare	_
64-35	11411-11416	these	_
64-36	11417-11422	rsFCs	_
64-37	11423-11430	between	_
64-38	11431-11434	the	_
64-39	11435-11436	9	_
64-40	11437-11447	drug-naïve	_
64-41	11448-11456	patients	_
64-42	11457-11460	and	_
64-43	11461-11464	the	_
64-44	11465-11467	86	_
64-45	11468-11476	patients	_
64-46	11477-11481	with	_
64-47	11482-11495	antipsychotic	_
64-48	11496-11506	treatments	_
64-49	11507-11508	(	_
64-50	11509-11510	P	_
64-51	11511-11512	<	_
64-52	11513-11517	0.05	_
64-53	11518-11519	,	_
64-54	11520-11531	uncorrected	_
64-55	11532-11533	)	_
64-56	11534-11535	.	_

Text=Correlations with clinical parameters To test potential correlations between the rsFCs of the IPL subregions with significant intergroup differences and the clinical variables, we extracted these rsFCs and calculated Spearman's correlation coefficients between these imaging measures and clinical parameters (i.e., PANSS scores, illness duration, and antipsychotic dosage).
65-1	11536-11548	Correlations	_
65-2	11549-11553	with	_
65-3	11554-11562	clinical	_
65-4	11563-11573	parameters	_
65-5	11574-11576	To	_
65-6	11577-11581	test	_
65-7	11582-11591	potential	_
65-8	11592-11604	correlations	_
65-9	11605-11612	between	_
65-10	11613-11616	the	_
65-11	11617-11622	rsFCs	_
65-12	11623-11625	of	_
65-13	11626-11629	the	_
65-14	11630-11633	IPL	_
65-15	11634-11644	subregions	_
65-16	11645-11649	with	_
65-17	11650-11661	significant	_
65-18	11662-11672	intergroup	_
65-19	11673-11684	differences	_
65-20	11685-11688	and	_
65-21	11689-11692	the	_
65-22	11693-11701	clinical	_
65-23	11702-11711	variables	_
65-24	11712-11713	,	_
65-25	11714-11716	we	_
65-26	11717-11726	extracted	_
65-27	11727-11732	these	_
65-28	11733-11738	rsFCs	_
65-29	11739-11742	and	_
65-30	11743-11753	calculated	_
65-31	11754-11762	Spearman	_
65-32	11763-11765	's	_
65-33	11766-11777	correlation	_
65-34	11778-11790	coefficients	_
65-35	11791-11798	between	_
65-36	11799-11804	these	_
65-37	11805-11812	imaging	_
65-38	11813-11821	measures	_
65-39	11822-11825	and	_
65-40	11826-11834	clinical	_
65-41	11835-11845	parameters	_
65-42	11846-11847	(	_
65-43	11848-11852	i.e.	_
65-44	11853-11854	,	_
65-45	11855-11860	PANSS	_
65-46	11861-11867	scores	_
65-47	11868-11869	,	_
65-48	11870-11877	illness	_
65-49	11878-11886	duration	_
65-50	11887-11888	,	_
65-51	11889-11892	and	_
65-52	11893-11906	antipsychotic	_
65-53	11907-11913	dosage	_
65-54	11914-11915	)	_
65-55	11916-11917	.	_

Text=For these correlation analyses, the threshold of significance was set at P <0.05, uncorrected.
66-1	11918-11921	For	_
66-2	11922-11927	these	_
66-3	11928-11939	correlation	_
66-4	11940-11948	analyses	_
66-5	11949-11950	,	_
66-6	11951-11954	the	_
66-7	11955-11964	threshold	_
66-8	11965-11967	of	_
66-9	11968-11980	significance	_
66-10	11981-11984	was	_
66-11	11985-11988	set	_
66-12	11989-11991	at	_
66-13	11992-11993	P	_
66-14	11994-11995	<	_
66-15	11996-12000	0.05	_
66-16	12001-12002	,	_
66-17	12003-12014	uncorrected	_
66-18	12015-12016	.	_

